Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Flawless balance sheet with limited growth.
Share Price & News
How has Spero Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SPRO's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: SPRO underperformed the US Biotechs industry which returned 22.8% over the past year.
Return vs Market: SPRO exceeded the US Market which returned 4.8% over the past year.
Price Volatility Vs. Market
How volatile is Spero Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?
4 months ago | Simply Wall StOne Thing To Remember About The Spero Therapeutics, Inc. (NASDAQ:SPRO) Share Price
5 months ago | Simply Wall StWhat Type Of Shareholder Owns Spero Therapeutics, Inc.'s (NASDAQ:SPRO)?
Is Spero Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SPRO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SPRO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SPRO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SPRO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SPRO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SPRO is good value based on its PB Ratio (3.3x) compared to the US Biotechs industry average (3.6x).
How is Spero Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SPRO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SPRO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SPRO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SPRO's revenue (70.5% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: SPRO's revenue (70.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SPRO's Return on Equity is forecast to be high in 3 years time
How has Spero Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SPRO is currently unprofitable.
Growing Profit Margin: SPRO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SPRO is unprofitable, and losses have increased over the past 5 years at a rate of -23.1% per year.
Accelerating Growth: Unable to compare SPRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: SPRO has a negative Return on Equity (-95.98%), as it is currently unprofitable.
How is Spero Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: SPRO's short term assets ($98.0M) exceed its short term liabilities ($22.7M).
Long Term Liabilities: SPRO's short term assets ($98.0M) exceed its long term liabilities ($4.7M).
Debt to Equity History and Analysis
Debt Level: SPRO is debt free.
Reducing Debt: SPRO has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SPRO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SPRO has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 22.8% each year.
What is Spero Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SPRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SPRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SPRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SPRO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SPRO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ankit Mahadevia (39yo)
Dr. Ankit Mahadevia, MD, MBA serves as the Chief Executive Officer and President of Spero Therapeutics, LLC. Dr. Mahadevia Co-founded of Spero Therapeutics, Inc. in 2013 and has been its Chief Executive Of ...
CEO Compensation Analysis
Compensation vs Market: Ankit's total compensation ($USD1.79M) is above average for companies of similar size in the US market ($USD1.35M).
Compensation vs Earnings: Ankit's compensation has increased whilst the company is unprofitable.
|Chief Operating Officer||2.83yrs||US$943.29k||0.0073% $20.0k|
|Chief Medical Officer||2.5yrs||US$936.29k||no data|
|Interim CFO & Treasurer||0.67yr||no data||no data|
|Chief Scientific Officer||6.25yrs||US$450.89k||no data|
|Senior Director of Investor Relations||no data||no data||no data|
|Vice President of People Strategy & Culture||1.67yrs||no data||no data|
|Chief Development Officer||1.08yrs||no data||0.012% $33.4k|
|Head of Clinical Microbiology||2.25yrs||no data||no data|
|Head of Clinical Operations||2.5yrs||no data||no data|
Experienced Management: SPRO's management team is considered experienced (2.5 years average tenure).
|Independent Director||7.33yrs||US$89.37k||no data|
|Independent Director||3yrs||US$99.37k||no data|
|Independent Chairman||no data||US$122.87k||0.080% $220.0k|
|Scientific Advisors||6.17yrs||no data||no data|
|Clinical Advisor||6.17yrs||no data||no data|
|Scientific Advisor||no data||no data||no data|
|Independent Director||4.83yrs||US$97.87k||no data|
|Clinical Advisor||6.17yrs||no data||no data|
|Clinical Advisor||6.17yrs||no data||no data|
Experienced Board: SPRO's board of directors are considered experienced (6.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.5%.
Spero Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Spero Therapeutics, Inc.
- Ticker: SPRO
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$275.359m
- Shares outstanding: 20.60m
- Website: https://sperotherapeutics.com
Number of Employees
- Spero Therapeutics, Inc.
- 675 Massachusetts Avenue
- 14th Floor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SPRO||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Nov 2017|
|2HA||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2017|
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/03 00:18|
|End of Day Share Price||2020/07/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.